NASDAQ:LRMR Larimar Therapeutics Q2 2025 Earnings Results & Report $1.99 -0.10 (-4.78%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$2.06 +0.07 (+3.57%) As of 10/15/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Larimar Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.41 versus the -$0.47 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeBefore Market OpensConference Call7:00 AM ET Larimar Therapeutics EPS ResultsActual EPS-$0.41Consensus EPS -$0.47Beat/MissBeat by +$0.06One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersLarimar Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsLarimar Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Larimar Therapeutics Q2 2025 Earnings FAQ Did Larimar Therapeutics beat earnings estimates for Q2 2025? Larimar Therapeutics (NASDAQ:LRMR) reported earnings of -$0.41 per share for Q2 2025, beating the consensus estimate of -$0.47. The report was announced on Thursday, August 14, 2025. When is Larimar Therapeutics' next earnings date? Larimar Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Larimar Therapeutics on the company's earnings history page. Larimar Therapeutics Earnings HeadlinesLarimar Therapeutics Names John Harlow As President And COOSeptember 30, 2026 | rttnews.comLarimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating OfficerSeptember 29, 2026 | globenewswire.comWall Street’s giving up on this trade. I’m not.Major banks have slashed their gold price targets - Morgan Stanley to $4450, JPMorgan to $4500 - after predicting $6000 gold earlier this year. Ross Givens, a former Wall Street insider, says bank targets tend to follow price rather than lead it. He still expects gold to reach $10000 an ounce this cycle. Givens points to a backdoor asset that gained 846%, 1668%, and 1915% in the last gold cycle. | Traders Agency (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)September 29, 2026 | theglobeandmail.comLarimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in PlaySeptember 3, 2026 | tipranks.comLarimar’s Phase 3 Friedreich’s Ataxia Trial Puts Nomlabofusp in the Investor SpotlightAugust 21, 2026 | tipranks.comSee More Larimar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Larimar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Larimar Therapeutics and other key companies, straight to your email. Email Address About Larimar TherapeuticsLarimar Therapeutics (NASDAQ:LRMR) is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich's ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar's approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms. Larimar is advancing nomlabofusp toward potential FDA approval. In June 2026, the company submitted the first module of its rolling Biologics License Application (BLA), seeking accelerated approval, with the remaining modules expected to be submitted in the second half of 2026. Larimar also plans to explore additional applications for its protein-delivery technology. Its shares trade on the Nasdaq under the symbol LRMR. View Larimar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
